BioCryst (BCRX) Stock Forecast & Price Target

Q: What is BCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 16.75.

Q: What is BCRX’s upside potential, based on the analysts’ average price target?

Biocryst Pharmaceuticals has 87.36% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is BCRX a Buy, Sell or Hold?

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

Q: What is Biocryst Pharmaceuticals’s price target?

The average price target for Biocryst Pharmaceuticals is 16.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 87.36% Increase from the current price of $8.94.

Q: What do analysts say about Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

Q: How can I buy shares of BCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

2,277 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCRX Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

BioCryst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$16.75

▲(87.36%Upside)

Based on 12 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $16.75 with a high forecast of $30.00 and a low forecast of $11.00. The average price target represents a 87.36% change from the last price of $8.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","10":"$10","17":"$17","24":"$24","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,10,17,24,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,12.212307692307693,13.694615384615386,15.176923076923078,16.65923076923077,18.141538461538463,19.623846153846152,21.106153846153845,22.588461538461537,24.07076923076923,25.553076923076922,27.035384615384615,28.517692307692307,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,11.193076923076923,11.656153846153847,12.11923076923077,12.582307692307692,13.045384615384616,13.508461538461539,13.971538461538461,14.434615384615384,14.897692307692308,15.36076923076923,15.823846153846155,16.286923076923078,{"y":16.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.73,10.750769230769231,10.771538461538462,10.792307692307693,10.813076923076924,10.833846153846155,10.854615384615386,10.875384615384615,10.896153846153846,10.916923076923077,10.937692307692307,10.958461538461538,10.97923076923077,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.05,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$16.75

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

0.67%

Upside

Reiterated

07/02/25

BioCryst faces significant financial challenges with persistent net losses and negative equity, heavily influencing its stock score. Despite positive earnings call outcomes and strategic corporate actions, the technical indicators suggest bearish momentum, and valuation metrics highlight high risk.

Laura ChicoWedbush

Wedbush

$16→$18

Buy

101.34%

Upside

Reiterated

06/30/25

BioCryst price target raised to $18 from $16 at WedbushBioCryst price target raised to $18 from $16 at Wedbush

Tazeen AhmadBank of America Securities

Bank of America Securities

$13→$15

Buy

67.79%

Upside

Reiterated

06/30/25

BioCryst's Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating

Serge BelangerNeedham

Needham

$17

Buy

90.16%

Upside

Reiterated

06/27/25

Needham Sticks to Its Buy Rating for BioCryst (BCRX)

Brian AbrahamsRBC Capital

RBC Capital

$13

Buy

45.41%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)

Gena WangBarclays

Barclays

$8→$11

Hold

23.04%

Upside

Reiterated

05/07/25

Barclays Sticks to Its Hold Rating for BioCryst (BCRX)

Liisa BaykoEvercore ISI

Evercore ISI

$12

Buy

34.23%

Upside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)

Jessica FyeJ.P. Morgan

J.P. Morgan

$10→$13

Buy

45.41%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$30

Buy

235.57%

Upside

Reiterated

05/06/25

H.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)

Maury RaycroftJefferies

Jefferies

$12→$14

Buy

56.60%

Upside

Reiterated

05/05/25

BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.

Stacy KuTD Cowen

TD Cowen

$20

Buy

123.71%

Upside

Reiterated

05/05/25

BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$20

Buy

123.71%

Upside

Initiated

04/28/25

BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald

Jonathan WollebenCitizens JMP

Citizens JMP

$18

Buy

101.34%

Upside

Reiterated

04/23/25

Citizens JMP reiterates Market Outperform Rating on BioCryst Pharma (BCRX)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on BioCryst Pharma (NASDAQ: BCRX).

Christopher RaymondPiper Sandler

Piper Sandler

$20

Buy

123.71%

Upside

Assigned

10/23/24

Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

0.67%

Upside

Reiterated

07/02/25

Laura ChicoWedbush

Wedbush

$16→$18

Buy

101.34%

Upside

Reiterated

06/30/25

BioCryst price target raised to $18 from $16 at WedbushBioCryst price target raised to $18 from $16 at Wedbush

Tazeen AhmadBank of America Securities

Bank of America Securities

$13→$15

Buy

67.79%

Upside

Reiterated

06/30/25

BioCryst's Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating

Serge BelangerNeedham

Needham

$17

Buy

90.16%

Upside

Reiterated

06/27/25

Needham Sticks to Its Buy Rating for BioCryst (BCRX)

Brian AbrahamsRBC Capital

RBC Capital

$13

Buy

45.41%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)

Gena WangBarclays

Barclays

$8→$11

Hold

23.04%

Upside

Reiterated

05/07/25

Barclays Sticks to Its Hold Rating for BioCryst (BCRX)

Liisa BaykoEvercore ISI

Evercore ISI

$12

Buy

34.23%

Upside

Reiterated

05/06/25

Evercore ISI Keeps Their Buy Rating on BioCryst (BCRX)

Jessica FyeJ.P. Morgan

J.P. Morgan

$10→$13

Buy

45.41%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$30

Buy

235.57%

Upside

Reiterated

05/06/25

H.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)

Maury RaycroftJefferies

Jefferies

$12→$14

Buy

56.60%

Upside

Reiterated

05/05/25

BioCryst Pharma (BCRX) PT Raised to $14 at JefferiesJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $12.00) while maintaining a Buy rating.

Stacy KuTD Cowen

TD Cowen

$20

Buy

123.71%

Upside

Reiterated

05/05/25

BioCryst's Orladeyo Surpasses Expectations: A Strong Buy Recommendation

Steven SeedhouseCantor Fitzgerald

Cantor Fitzgerald

$20

Buy

123.71%

Upside

Initiated

04/28/25

BioCryst initiated with an Overweight at Cantor FitzgeraldBioCryst initiated with an Overweight at Cantor Fitzgerald

Jonathan WollebenCitizens JMP

Citizens JMP

$18

Buy

101.34%

Upside

Reiterated

04/23/25

Christopher RaymondPiper Sandler

Piper Sandler

$20

Buy

123.71%

Upside

Assigned

10/23/24

Piper Sandler Sticks to Its Buy Rating for BioCryst (BCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

1 Month

xxx

Success Rate

15/23 ratings generated profit

Average Return

+7.83%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +7.83% per trade.

3 Months

xxx

Success Rate

8/15 ratings generated profit

Average Return

+7.34%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +7.34% per trade.

1 Year

Brian AbrahamsRBC Capital

Success Rate

13/15 ratings generated profit

Average Return

+25.17%

reiterated a buy rating 10 days ago

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +25.17% per trade.

2 Years

xxx

Success Rate

13/15 ratings generated profit

Average Return

+31.51%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +31.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCRX has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 16.75.

Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is <$0.01 with a range of -$0.01 to $0.03. The previous quarter’s EPS was $0.00. BCRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $149.22M with a range of $143.07M to $156.03M. The previous quarter’s sales results were $145.53M. BCRX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BCRX has Outperformed its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 16.75.

What is BCRX’s upside potential, based on the analysts’ average price target?

Biocryst Pharmaceuticals has 87.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCRX a Buy, Sell or Hold?

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Biocryst Pharmaceuticals’s price target?

The average price target for Biocryst Pharmaceuticals is 16.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $11.00. The average price target represents 87.36% Increase from the current price of $8.94.

What do analysts say about Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioCryst (BCRX) Stock Forecast & Price Target

BCRX Analyst Ratings

BCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioCryst

BCRX Analyst Recommendation Trends

BCRX Financial Forecast

BCRX Earnings Forecast

BCRX Sales Forecast

BCRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts